Bidding War for Stada Unlikely to Lift Price After Rally
- Cinven’s bid is 68% above price prior to takeover rumors
- Drugmaker can’t emulate biotechs with traditional drug lineup
This article is for subscribers only.
Investors counting on a bidding war to drive up the price of German drugmaker Stada Arzneimittel AG well past its $3.66 billion in market value may be out of luck.
The German maker of generic medicines this week said it had two offers, including one from Cinven Ltd. valuing it at about 56 euros-a-share. And people familiar with the matter said other private equity firms including Bain Capital, Permira and CVC Capital Partners are closely monitoring the situation as they consider whether to bid.